Solid Biosciences Inc.
NASDAQ:SLDBBiotechnology
+$0.27 today
- Market cap
- $708.73M
- Beta
- 2.43
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$1.75
Volume 1.21M
Average 1.39M
SLDB Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Solid Biosciences Inc.NASDAQ: SLDB
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue dips below year-ago levels
Q1 FY2026 cost of revenue of $395K fell 2.9% year over year, behind the +91.9% change in trailing-twelve-month cost of revenue.
Context
- Cost of revenue increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -2.9% toward the trailing-twelve-month pace of +91.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 1.64M USD
- Year-over-year change
- -33.4%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.64M | -33.4% |
| FY2024 | 2024-12-31 | 2.46M | -4.9% |
| FY2023 | 2023-12-31 | 2.58M | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Cost of Revenue vs competitors
How SLDB compares with its peers on the latest reported figures
- SLDB's LTM Mar 2026 cost of revenue of $781K is the 8th highest of the 10 companies compared; the peer median is $38.25M.
- Its year-over-year change of +91.9% is the 4th highest of 8, against a peer median of +12.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $821.4M | +102.3% | +84.7% | 37.6% | |
| LTM Jun 2026 | $180.19M | +250.5% | +17.1% | 17.9% | |
| LTM Mar 2026 | $99.22M | -12.1% | -54.4% | 112.4% | |
| LTM Mar 2026 | $42.41M | -26.6% | — | — | |
| LTM Mar 2026 | $38.25M | +12.7% | -0.0% | — | |
| LTM Mar 2026 | $6.67M | -73.5% | — | 8.4% | |
| LTM Mar 2026 | $1.72M | +351.6% | — | — | |
| LTM Mar 2026 | $781K | +91.9% | — | — | |
| LTM Sep 2026 | $590K | — | — | — | |
| LTM Jun 2026 | $521K | — | — | — | |
| Peer median (excluding SLDB) | $38.25M | +12.7% | +8.5% | 27.7% | |
Competitors are the stored peer set for SLDB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 13.62M | 8.09M | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 2.58M | 2.46M | 1.64M |
| Gross Profit | 13.62M | 8.09M | (2.58M) | (2.46M) | (1.64M) |
| Gross Margin | 100.0% | 100.0% | — | — | — |
| Research & Development | 58.74M | 78.42M | 76.56M | 96.43M | 140.33M |
| Selling, General & Admin | 27.14M | 28.95M | 27.75M | 33.3M | 38.88M |
| Operating Expenses | 85.87M | 114.55M | 101.73M | 127.27M | 177.57M |
| Depreciation & Amortization | 2.96M | 2.41M | 2.58M | 2.46M | 1.64M |
| EBITDA | (69.22M) | (96.87M) | (93.43M) | (121.9M) | (172.69M) |
| EBITDA Margin | -508.3% | -1196.8% | — | — | — |
| Operating Income | (72.25M) | (106.45M) | (104.32M) | (129.73M) | (179.21M) |
| Operating Margin | -530.5% | -1315.2% | — | — | — |
| Interest Income | 64K | 2.62M | 7.14M | 9.47M | 9.9M |
| Interest Expense | 0 | 0 | 0 | 340K | 0 |
| Other Income / Expenses | 66K | 20.47M | 8.3M | 5.03M | 4.88M |
| Income Before Tax | (72.19M) | (85.98M) | (96.02M) | (124.7M) | (174.33M) |
| Pre-Tax Margin | -530.0% | -1062.3% | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (72.19M) | (85.98M) | (96.02M) | (124.7M) | (174.33M) |
| Net Margin | -530.0% | -1062.3% | — | — | — |
| EPS (Basic) | (10.14) | (10.10) | (4.83) | (3.06) | (1.99) |
| EPS (Diluted) | (10.14) | (10.10) | (4.83) | (3.06) | (1.99) |
| Weighted Avg Shares | 7.12M | 8.51M | 19.88M | 40.82M | 87.5M |
| Weighted Avg Shares (Diluted) | 7.12M | 8.51M | 19.88M | 40.82M | 87.5M |
Solid Biosciences Inc.
NASDAQ:SLDB
Intrinsic Alpha fair value
Locked
Current Price
$6.35
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.